Ozanimod for the treatment of relapsing remitting multiple sclerosis

@article{Rasche2018OzanimodFT,
  title={Ozanimod for the treatment of relapsing remitting multiple sclerosis},
  author={L. Rasche and F. Paul},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={2073 - 2086}
}
  • L. Rasche, F. Paul
  • Published 2018
  • Medicine
  • Expert Opinion on Pharmacotherapy
    • ABSTRACT Introduction: Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to its low receptor specificity and have prompted the development of next generation sphingosine 1-phosphate receptor… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov
    9 Citations
    Background Citations
    2
    9 Citations
    Citation Type

    Citation Type

    Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
    • PDF
    Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    • 4
    Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
    • 3
    Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?
    • 1
    Flammer Syndrome and Autoimmune Inflammatory Conditions of the Central Nervous System: Multifactorial Interrelations
    Effects of Massage Therapy on Multiple Sclerosis: a Case Report
    • Amy Frost-Hunt
    • Medicine
    • International journal of therapeutic massage & bodywork
    • 2020
    • PDF
    Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
    • PDF
    New era of therapy for endocrine autoimmune disorders
    Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
    • PDF

    References

    SHOWING 1-10 OF 207 REFERENCES
    Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    • 17
    An update on cladribine for relapsing-remitting multiple sclerosis
    • 11
    Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
    • 90
    Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    • 1,792
    • PDF
    Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
    • 145
    • Highly Influential
    A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    • 2,061
    • PDF
    Both cladribine and alemtuzumab may effect MS via B-cell depletion
    • 49
    • PDF
    Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
    • 317
    • PDF
    Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
    • 12
    Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
    • Ron Milo
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2015
    • 15